Over the past year, numerous studies in the peer reviewed and preprint literature have
reported on the virological, epidemiological and clinical characteristics of the coronavirus …

Despite many countries rapidly revising their strategies to prevent contagions, the number of
people infected with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Abstract Background The Ad26. COV2. S vaccine is a recombinant, replication-incompetent
human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome …

T cell responses play an important role in protection against beta-coronavirus infections,
including SARS-CoV-2, where they associate with decreased COVID-19 disease severity …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein is the
main antigen in all approved COVID-19 vaccines and is also the only target for monoclonal …

Knowledge of the epitopes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) targeted by T cells in recovered (convalescent) individuals is important for understanding …

Patients with chronic lymphocytic leukemia (CLL) or monoclonal B-lymphocytosis (MBL)
have impaired response to COVID-19 vaccination. A total of 258 patients (215 with CLL and …

The emergence of SARS-CoV-2 variants of concern (VOC) is driven by mutations that
mediate escape from neutralizing antibodies. There is also evidence that mutations can …

Abstract SARS-CoV-2, the culprit pathogen of COVID-19, elicits prominent immune
responses and cytokine storms. Intracellular Cl− is a crucial regulator of host defense …

Targeted synthetic vaccines have the potential to transform our response to viral outbreaks,
yet the design of these vaccines requires a comprehensive knowledge of viral immunogens …